Home Cart Sign in  
Chemical Structure| 828-51-3 Chemical Structure| 828-51-3

Structure of 1-Adamantanecarboxylic acid
CAS No.: 828-51-3

Chemical Structure| 828-51-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Josephine Bicknell ; Sidhaesh A. Agarwal ; Kyle J. Petersen ; Jesus Daniel Loya ; Nicholas Lutz ; Paulina M. Sittinger , et al.

Abstract: Lipophilic aggregation using adamantanes is a widely exploited molecular property in medicinal and materials chemistry. Adamantanes are traditionally installed to molecular units via covalent bonds. However, the noncovalent installation of adamantanes has been relatively underexplored and presents the potential to bring properties associated with adamantanes to molecules without affecting their intrinsic properties (e.g., pharmacophores). Here, we systematically study a series of adamantanecarboxylic acids with varying substitution levels of methyl groups and their cocrystals with bipyridines. Specifically, single-crystal X-ray diffraction shows that while the directionality of single-component adamantanes is notably sensitive to changes in methyl substitution, hydrogen-bonded cocrystals with bipyridines show consistent and robust packing due to π-stacking predominance. Our observations are supported by Hirshfeld surface and energy framework analyses. The applicability of cocrystal formation of adamantanes bearing carboxylic acids was used to generate the first cocrystals of adapalene, an adamantane-bearing retinoid used for treating acne vulgaris. We envisage our study to inspire noncovalent (i.e., cocrystal) installation of adamantanes to generate lipophilic aggregation in multicomponent systems.

Purchased from AmBeed: ; ; ; ; ;

Alternative Products

Product Details of [ 828-51-3 ]

CAS No. :828-51-3
Formula : C11H16O2
M.W : 180.24
SMILES Code : O=C(C12CC3CC(C2)CC(C3)C1)O
MDL No. :MFCD00074720
InChI Key :JIMXXGFJRDUSRO-UHFFFAOYSA-N
Pubchem ID :13235

Safety of [ 828-51-3 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 828-51-3 ] Show Less

Physicochemical Properties

Num. heavy atoms 13
Num. arom. heavy atoms 0
Fraction Csp3 0.91
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 50.16
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

37.3 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.84
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.62
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.29
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.48
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.95
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.24

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.54
Solubility 0.517 mg/ml ; 0.00287 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-3.05
Solubility 0.159 mg/ml ; 0.000885 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.32
Solubility 8.65 mg/ml ; 0.048 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.54 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.56

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

3.76

Application In Synthesis of [ 828-51-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 828-51-3 ]

[ 828-51-3 ] Synthesis Path-Downstream   1~15

  • 1
  • [ 828-51-3 ]
  • [ 6995-79-5 ]
  • [ 56432-86-1 ]
  • 2
  • [ 828-51-3 ]
  • [ 3236-48-4 ]
  • C30H44O4 [ No CAS ]
  • 3
  • [ 828-51-3 ]
  • [ 53951-84-1 ]
  • [ 753487-78-4 ]
  • 6
  • [ 828-51-3 ]
  • [ 116668-47-4 ]
  • [ 1268629-34-0 ]
  • 7
  • [ 828-51-3 ]
  • [ 116668-47-4 ]
  • [ 1268629-39-5 ]
  • 8
  • [ 33893-89-9 ]
  • [ 2094-72-6 ]
  • [ 828-51-3 ]
  • [ 1415251-74-9 ]
YieldReaction ConditionsOperation in experiment
50% With pyridine;Inert atmosphere; Reflux; The reaction was performed with 5-(2'-pyridyl)-1H-tetrazole (500 mg, 3.40 mmol) and 1-adamantanecarboxylic acid chloride (675 mg, 3.40 mmol, Acros) in pyridine (3.5 mL). The reaction mixture was extracted with ether/H2O. The organic layer was washed with water (to remove pyridine) and evaporated. Purification by column chromatography was performed on silica (10 g). Elution with CH2Cl2 removed the impurities. Elution with 0.5% of CH3OH in CH2Cl2 recovered the product. It was re-dissolved in ether, and hexane (20 mL) was added. The ether was rotor-evaporated to leave a suspension of the product in hexane. The suspension was cooled to -15 C overnight and filtered. The product was washed with cold hexane. The product purified in this way contained 10% of 1-adamantanecarboxylic acid (detected by 1H and 13C NMR). To remove the acid, the product was sonicated in saturated aqueous solution of Na2CO3 for 10 min and extracted with ether. The organic layer was washed with saturated aqueous solution of Na2CO3 and water. It was evaporated, and the extraction with Na2CO3 (aq. sat.) and ether was repeated one more time. White solid: 477 mg (1.70 mmol, 50%). Anal. Calc. for C17H19N3O (MW 281.35): C, 72.57; H, 6.81; N, 14.94. Found: C, 72.54; H, 6.87; N, 14.74%. 1H NMR (400 MHz, [D6]dmso): delta = 8.79-8.74 (m, 1H), 8.19-8.13 (m, 1H), 8.03 (td, J = 8.0, 1.6 Hz, 1H), 7.62 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 2.10-2.04 (m, br, 9H), 1.77 (br, 6H) ppm. 13C NMR (100 MHz, CD2Cl2): delta = 173.68, 163.90, 150.34, 144.25, 137.28, 125.72, 123.00, 40.12, 36.44, 34.71, 28.13 ppm. GC-EI+ MS: m/z 281 (M+, 100%).
  • 10
  • [ 828-51-3 ]
  • [ 40505-27-9 ]
  • 4-O-(1-adamantanecarboxylicacid)-4-deoxy-4'-demethylepipodophyllotoxin [ No CAS ]
  • 11
  • [ 828-51-3 ]
  • [ 47689-67-8 ]
  • [ 53308-95-5 ]
  • C41H56N5O5Pol [ No CAS ]
  • 12
  • [ 828-51-3 ]
  • [ 446065-11-8 ]
  • [ 77817-08-4 ]
  • 13
  • [ 828-51-3 ]
  • [ 180683-64-1 ]
  • C22H36N2O3 [ No CAS ]
  • 14
  • [ 7343-34-2 ]
  • [ 828-51-3 ]
  • 3-(3,5-dimethyl-1,2,4-triazol-1-yl)-adamantane-1-carboxylic acid [ No CAS ]
YieldReaction ConditionsOperation in experiment
47% With sulfuric acid; potassium nitrate; at 0 - 20℃; for 4.5h;Sealed tube; General procedure: General method for preparation of all presented compounds is described below. Completion ofthe reactions was determined by TLC with bromocresol green solution as a stain.10 mmol of the appropriate azole (1H-1,2,4-triazole, 3-methyl-1H-1,2,4-triazole,<strong>[7343-34-2]3,5-dimethyl-1H-1,2,4-triazole</strong>, 1H-tetrazole or 5-methyl-1H-tetrazole) and 10 mmol of 1-adamantanecarboxylic acid were placed in 20 mL screwcap vial and dissolved in 10 mL of 98% concentratedsulfuric acid. The mixture was cooled to 0 C using an ice bath. After cooling, 10 mmol (1010mg) of potassium nitrate were added in small portions over the period of 30 min. Once all of thenitrate has been added, the ice bath was removed, and the mixture was stirred for another 4 h atroom temperature. After 4 h of stirring, reaction mixture was poured on 100 g of crushed ice withshaking and allowed to stand until it reached room temperature. Quenched mixture was filtered andneutralized with saturated NaHCO3 solution. Precipitate was filtered, washed with copious amountsof distilled water and dried in vacuum desiccator. Products are suciently pure for the synthesis ofcoordination compounds, but for the analysis the small portions of each compound were recrystallizedfrom the mixture of water/MeOH (9:1).
  • 15
  • [ 828-51-3 ]
  • [ 118994-89-1 ]
  • C16H21NO3 [ No CAS ]
  • C26H35NO3 [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 828-51-3 ]

Aliphatic Cyclic Hydrocarbons

Chemical Structure| 828-52-4

A175809 [828-52-4]

4-(Hydroxymethyl)bicyclo[2.2.2]octane-1-carboxylic acid

Similarity: 1.00

Chemical Structure| 14670-94-1

A189504 [14670-94-1]

3,5-Dimethyladamantane-1-carboxylic acid

Similarity: 1.00

Chemical Structure| 699-55-8

A488085 [699-55-8]

Bicyclo[2.2.2]octane-1-carboxylic acid

Similarity: 1.00

Chemical Structure| 1123-25-7

A167457 [1123-25-7]

1-Methylcyclohexanecarboxylic acid

Similarity: 1.00

Chemical Structure| 1086399-13-4

A571534 [1086399-13-4]

Spiro[2.5]octane-6-carboxylic acid

Similarity: 0.96

Carboxylic Acids

Chemical Structure| 828-52-4

A175809 [828-52-4]

4-(Hydroxymethyl)bicyclo[2.2.2]octane-1-carboxylic acid

Similarity: 1.00

Chemical Structure| 14670-94-1

A189504 [14670-94-1]

3,5-Dimethyladamantane-1-carboxylic acid

Similarity: 1.00

Chemical Structure| 699-55-8

A488085 [699-55-8]

Bicyclo[2.2.2]octane-1-carboxylic acid

Similarity: 1.00

Chemical Structure| 1123-25-7

A167457 [1123-25-7]

1-Methylcyclohexanecarboxylic acid

Similarity: 1.00

Chemical Structure| 1086399-13-4

A571534 [1086399-13-4]

Spiro[2.5]octane-6-carboxylic acid

Similarity: 0.96